Euroline myositis line blot assay

Manufactured by EUROIMMUN

Sourced in Germany

The Euroline myositis line-blot assay is a laboratory diagnostic tool used for the detection of autoantibodies associated with myositis, a group of inflammatory muscle disorders. The assay utilizes a line-blot format to provide a qualitative analysis of the presence of these autoantibodies in patient samples.

Automatically generated - may contain errors

Lab products found in correlation

Eurolinescan, by EUROIMMUN (1 mentions)

4 protocols using euroline myositis line blot assay

Anti-SRP Antibody IMNM Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

All initially screened patients met either the Bohan and Peter criteria or the European Neuromuscular Centre criteria (ENMC) for IIMs between March 2010 and February 2020. All patients with IMNM were confirmed by muscle pathology. IMNM patients whose sera carried anti-SRP antibodies were selected for study. The anti-SRP antibody in the serum of patients was detected by the Euroline myositis line-blot assay of Euroimmun (Lübeck, Germany) according to the instructions of the manufacturer. Clinical and laboratory data were retrieved from their medical records, such as age, skin manifestations, muscle strength, muscle pathology, pulmonary function tests (PFTs), high-resolution computed tomography (HRCT), lung biopsy, presence of other MAAs, treatment and follow-up. If anti-SRP-positive IMNM patients were combined with other MSAs or other connective tissue diseases (CTDs), they were excluded.
This study was approved by the Ethics Institutional Review Board of the China-Japan Friendship Hospital.

Ge Y., Yang H., Xiao X., Liang L., Lu X, & Wang G. (2022). Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies. BMC Pulmonary Medicine, 22, 14.

+ Open protocol

+ Expand

Anti-U1RNP Autoantibody-Positive IIMs

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

This was a retrospective non-interventional study, 916 adult consecutive patients with IIMs from the China–Japan Friendship Hospital who met either the Bohan and Peter criteria or the European Neuromuscular Centre criteria or the 2017 EULAR/ACR criteria for IIMs and were positive for anti-U1RNP antibodies were enrolled between Dec 2011 and Dec 2021.^{12 (link)–15 (link, link, link)} The anti-nuclear antibody profile [antigen including Ro-52, Sjogren’s syndrome A (SSA), RNP, etc.] was assessed by immunoblotting using commercial kits [EUROLINE antinuclear antibody (ANA) profile] from Euroimmun. Serum MSAs and MAAs were detected via the Euroline myositis line-blot assay of Euroimmun (Lübeck, Germany) according to the manufacturer’s protocol. We documented the response to treatment. The reporting of this study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology statement.^{16 (link)}

Ge Y., Yang H., Jiang W., Tian X., Lu X, & Wang G. (2023). Clinical characteristics of myositis patients with isolated anti-U1 ribonucleoprotein antibody resemble immune-mediated necrotizing myopathy. Therapeutic Advances in Musculoskeletal Disease, 15, 1759720X231181336.

+ Open protocol

+ Expand

Myositis Autoantibody Detection Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The Euroline myositis line-blot assay of Euroimmun (Lübeck, Germany) was performed according to the instructions of the manufacturer. This blot allows for detection of multiple MSA, namely antibodies against SRP, EJ, OJ, Mi-2α, Mi-2β, TIF1-γ, MDA5, NXP2, SAE1, PL-12, PL-7 and Jo-1, and MAA, specifically antibodies against Ku, PM/Scl-75 and PM/Scl-100. Anti-Ro52 was excluded from the analysis because anti-Ro52 is not specific for myositis or connective tissue diseases [12 (link)]. HGMCoAR antibodies and cN1A antibodies have not been systematically tested in this cohort of patients, since they are not part of the above-mentioned assay.
All immunoblot strips were analyzed with the EUROLineScan (Euroimmun) according to the manufacturers recommendations, and scored negative, weakly positive (+) and positive (++ or +++). This corresponds to intensity levels 0–10, 11–25 and > 25, respectively. The strong positive intensity level (>50) was not reported by all centers, therefore all intensity levels >25 were included in the positive category.

Platteel A.C., Wevers B.A., Lim J., Bakker J.A., Bontkes H.J., Curvers J., Damoiseaux J., Heron M., de Kort G., Limper M., van Lochem E.G., Mulder A.H., Saris C.G., van der Valk H., van der Kooi A.J., van Leeuwen E.M., Veltkamp M., Schreurs M.W., Meek B, & Hamann D. (2019). Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients. Journal of Translational Autoimmunity, 2, 100013.

+ Open protocol

+ Expand

Anti-MDA5 Autoantibody in Chinese DM Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

A cohort of 200 Chinese patients, diagnosed with DM with anti-MDA5, were
identified at the Rheumatology Department of the China-Japan Friendship Hospital
from January 2016 to October 2020. The anti-MDA5 antibody in the serum of
patients was detected by the Euroline myositis line-blot assay of Euroimmun
(Lübeck, Germany). Clinical manifestations, laboratory data, and radiographic
data were extracted from medical records. This study was approved by the
Research Review Committee (RRC) and the Ethical Review Committee (ERC) of the
China-Japan Friendship Hospital (IRB number is 2016-117). Written informed
consent was obtained from all enrolled patients at admission. In this
retrospective non-interventional study, all patients’ data were anonymously
surveyed.

Ding Y, & Ge Y. (2022). Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome. Therapeutic Advances in Chronic Disease, 13, 20406223221098128.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!